Based in Lausanne, ADC Therapeutics is a commercial-stage biotechnology company tackling cancer with its next-generation, targeted antibody-drug conjugates (ADCs). The company’s ZYNLONTA is a CD19-directed ADC.
The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
ZYNLONTA is also in development in combination with other agents. In addition to the FDA approval, a Marketing Authorization Application (MAA) for ZYNLONTA has been validated by the European Medicines Agency (EMA) and is under review by the EMA’s Committee for Medicinal Products for Human Use (CHMP).
Making ZYNLONTA available to patients worldwide
Japanese pharma company Mitsubishi Tanabe Pharma Corporation (MTPC) has received exclusive rights to develop and commercialize ZYNLONTA for all hematologic and solid tumor indications in Japan. Under the terms of the agreement, ADC Therapeutics will receive an upfront payment of USD 30 million and up to an additional USD 205 million in milestones if certain development and commercial events are achieved.
Additionally, the Vaud-based company will receive royalties ranging in percentage from the high teens to the low twenties based on net sales of the product in Japan. MTPC will conduct clinical studies of ZYNLONTA in Japan and will have the right to participate in any global clinical studies of the product by bearing a portion of the costs of the study.
